S100A8 and S100A9 expression is a crucial factor for dedifferentiation in thyroid carcinoma

Anticancer Research

Volumn 29, Issue 10, 2009, Pages 4157-4161

  Ito, Yasuhiro ^a   Arai, Kazumori ^b   Nozawa, Ryushi ^c   Yoshida, Hiroshi ^a   Hirokawa, Mitsuyoshi ^a   Fukushima, Mitsuhiro ^a   Inoue, Hiroyuki ^a   Tomoda, Chisato ^a   Kihara, Minoru ^a   Higashiyama, Takuya ^a   Takamura, Yuuki ^a   Miya, Akihiro ^a   Kobayashi, Kaoru ^a   Matsuzuka, Fumio ^a   Miyauchi, Akira ^a  

^a KUMA HOSPITAL   (Japan)

^b SHIZUOKA GENERAL HOSPITAL   (Japan)

^c UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

Immunohistochemistry; S100A8; S100A9; Thyroid carcinoma; Undifferentiated carcinoma

Indexed keywords

CALGRANULIN A; CALGRANULIN B; MONOCLONAL ANTIBODY;

ADULT; ANTIBODY DETECTION; ARTICLE; BONE MARROW CELL; COMPLEX FORMATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; TUMOR DIFFERENTIATION;

CALGRANULIN A; CALGRANULIN B; CELL DIFFERENTIATION; HUMANS; IMMUNOHISTOCHEMISTRY; THYROID NEOPLASMS;

EID: 71949111514     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Aldinger KA, Samaan NA, Ibanez M and Hill CS Jr: Anaplastic carcinoma of the thyroid: a review of 84 cases of spindle and giant-cell carcinoma of the thyroid. Cancer 41: 2267-2275, 1978. (Pubitemid 8370197)
2. Sakamoto A, Kasai N and Sugano H: Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high risk group of papillary and follicular carcinomas. Cancer 52: 1849-1855, 1983.
3. Carcangiu ML, Zampi G and Rosai J: Poorly differentiated ("insular") thyroid carcinoma. A reinterpretation of Langhans' "Wuchernde Struma". Am J Surg Pathol 8: 655-668, 1984.
4. Sobrinho-Simoes M, Carcangiu ML, Albores-Saavedra J et al: Poorly differentiated carcinoma. In: Pathology and Genetics of Tumours of Endocrine Organs. DeLeillis RA, Lloyd RV, Heitz PU et al. (eds.). Pathology and genetics of tumous of endocrine organs, Lyon, IARC Press, pp. 73-76, 2004.
5. Raue R, Kkotzerke J, Reinwein D, Schroder S, Roher HD, Deckart H, Hofer R, Ritter M, Seif F, Buhr H, Beyer J, Schober O, Becker W, Neumann H, Calvi J, Winter J and Vogt H: Prognostic factors in medullary thyroid carcinoma: evaluation of 741 patients from the German medullary thyroid carcinoma register. Clin Invest 71: 7-12, 1993.
6. Marenholz I, Heizmann CW and Fritz G: S100 proteins in mouse and man: from evolution to function and pathology (including an update of nomenclature). Biochem Biophys Res Commun 332: 1111-1122, 2004. (Pubitemid 39164640)
7. Donato R: Intracellular and extracellular roles of S100 proteins. Microsc Res Tech 60: 540-551, 2003.
8. Heizmann CW, Fritz G and Schafer BW: S100 proteins: structure, functions and pathology. Front Biosci 7: 1356-1368, 2002.
9. Gebhardt C, Nemeth J, Angel P and Hess J: S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol 72: 1622-1631, 2006.
10. Odink K, Cerletti N, Bruggen J, Clerc RG, Tarcsay L, Zwadio G, Gerhards G, Schlegel R and Sorg C: Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis. Nature 330: 80-82, 1987. (Pubitemid 17152420)
11. Hobbs JA, May R, Tanousis K, McNeill E, Mathies M, Gebhardt C, Herderson R, Robinson MJ and Hogg N: Myeloid cell funtion in MRP-14 (S100A9) null mice. Mol Cell Biol 23: 2564-2576, 2003. (Pubitemid 36351035)
12. Wilkinson MM, Busuttil A, Hayward C,Brock DJH, Dorin JR and van Heyningen V: Expression pattern of two related cystic fibrosis-associated calcium-binding proteins in normal and abnormal tissues. J Cell Sci 91: 221-230, 1988.
13. Arai K, Yamada T and Nozawa R: Immunohistochemical investigation of migration inhibitory factor-related protein (MRP)-14 expression in hepatocellular carcinoma. Med Oncol 17: 183-188, 2000. (Pubitemid 30655739)
14. Arai K, Teratani T, Nozawa R and Yamada T: Immunohistochemical investigation of S100A9 expression in pulmonary adenocarcinoma: S100A9 expression is associated with tumor differentiation. Oncol Rep 8: 591-596, 2001. (Pubitemid 33758460)
15. Arai K, Teratani T, Kuruto-Niwa R, Yamada T and Nozawa R: S100A9 expression in invasive ductal carcinoma of the breast: S100A9 expression in adenocarcinoma is closely associated with poor tumour differentiation. Eur J Cancer 40: 1179-1187, 2004. (Pubitemid 38526336)
16. Ito Y, Arai K, Nozawa R, Yoshida H, Tomoda C, Uruno T, Miya A, Kobayashi K, Matsuzuka F, Kuma K, Kakudo K and Miyauchi A: S100A9 expression is significantly linked to dedifferentiation of thyroid carcinoma. Pathol Res Pract 201: 551-556, 2005. (Pubitemid 41363948)
17. Arai K, Mizuno K, Yamada T and Nozawa R: Immunohistochemical evaluation of MRP-14 expression in epithelioid granuloma using monoclonal antibody 60B 8. J Invest Allergol Clin Immunol 9: 21-26, 1999. (Pubitemid 29149984)
18. Teratani T, Watanabe T, Kuwahara F, Kumagai H, Kobayashi S, Aoki U, Ishikawa A, Arai K and Nozawa R: Induced transcriptional expression of calcium-binding protein S100A1 and S100A10 genes in human renal cell carcinoma. Cancer Lett 175: 71-77, 2002. (Pubitemid 33153046)
19. Teratani T, Watanabe T, Yamahara K, Kumagai H, Ishikawa A, Arai K and Nozawa R: Restricted expression of calcium-binding protein S100A5 in human kidney. Biochem Biophys Res Commun 291: 623-627, 2002. (Pubitemid 34687391)
20. Arai K, Takano S, Teratani T, Ito Y, Yamada T and Nozawa R: S100A8 and S100A9 overexpression is associated with poor pathological parameters in invasive ductal carcinoma of the breast. Curr Cancer Drug Targets 8: 243-252, 2008. (Pubitemid 351881350)
21. Hermani A, Hess J, De Servi B, Medunjanin S, Grobholz R, Trojan L, Angel P and Mayer D: Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin Cancer Res 11: 5146-5152, 2005. (Pubitemid 41003699)
22. Hermani A, De Servi B, Medunjanin S, Tessier PA and Mayer D: S100A8 and S100A9 activate MAPkinase and NF-κB signaling pathways and translocation of RAGE in human prostate cancer cells. Exp Cell Res 312: 184-197, 2006. (Pubitemid 41721180)
23. Manitz MP, Horst V, Seeliger S, Strey A, Skryabin BV, Gunzer M, Frings W, Schonlau F, Roth J, Sorg C and Nacken W: Loss of S100A9 (MRP14) results in reduced interleukin-8-induced CD11β surface expression, a polarized microfilament system, and diminished responsiveness to chemoattractants in vitro. Mol Cell Biol 222: 1034-1043, 2003. (Pubitemid 36133519)
24. Hunter MJ and Chazin WJ: High level expression and dimer characterization of the S100 EF-hand proteins, migration inhibitory factor-related proteins 8 and 14. J Biol Chem 273: 12427-12435, 1998.
25. Vogl T, Ludwig S, Goebeler M, Strey A, Thorey IS, Reichelt R, Foell D, Gerke V, Manitz MP, Nacken W, Werner S, Sorg C and Roth J: MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes. Blood 104: 4260-4268, 2004. (Pubitemid 39620181)
26. Hiratsuka S, Watanabe A, Aburatani H and Maru Y: Tumour-mediated up-regulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 8: 1369-1375, 2006. (Pubitemid 44835111)
27. Moon A, Yong HY, Song JI, Cukovic D, Salagrama S, Kaplan D, Putt D, Kim H, Dombkowski A and Kim HR: Global gene expression prolifling unveils S100A8/A9 as candidate markers in H-ras-mediated human breast epithelial cell invasion. Mol Cancer Res 6: 1544-1553, 2008.
28. Turovskaya O, Foell D, Sinha P, Vogl T, Newlin R, Navak J, Nguven M, Olsson A, Nawroth PP, Bierhaus A, Varki N, Kronenberg M, Freeze HH, and Srikrishna G: RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis 29: 2035-2043, 2008.
29. Barkett M and Gilmore TD: Control of apoptosis β Bel/ NF-κB transcription factors. Oncogene 19: 6910-6924, 1999.
30. Pacifico F, Mauro C, Barone C, Crescenzi E, Mellone S, Monaco M, Chiappetta G, Terrazzano G, Liguoro D, Vito P, Consiglio E, Formisano S and Leonardi A: Oncogenic and anti-apoptotic activity of NF-κB in human thyroid carcinomas. J Biol Chem 279: 54610-54619, 2004. (Pubitemid 40053204)
31. Visconti R, Cerutti J, Battista S, Felele M, Trapasso F, Zeki K, Miano MP, de Nigris F, Casalino L, Curcio F, Santoro M and Fusco A. Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NF-κB p65 protein expression. Oncogene 15: 1987-1994, 1997.